About GMIS' Production System
GMIS’ production system provides the company with several key competitive advantages in producing these radioisotopes, namely:
- Significantly lower production facility costs at MSC existing facilities; no reactor necessary
- Ease of licensing due to existing MSC radiological licenses
- Only company not using HEU or LEU and able to utilize existing distribution network
- Ability to scale to meet growing market demand
About GMIS and Mo99
The current process for making Mo99 starts in six nuclear reactors located around the world, none of which are in North America. These nuclear reactors are 50 years old on average and are experiencing growing amounts of down time and constantly threatening the continuous and needed supply of Mo99 to facilities servicing patients throughout the United States. The process to produce Mo99 also requires the use of weapons-grade uranium as a target material, which is in short supply and needs secure transport when shipped from the United States to the foreign countries where these nuclear reactors reside. Logistical problems abound in getting this uranium overseas, bringing the still weapons-grade uranium waste back to the U.S. for disposal and shipping the short-lived Mo99 (half-life is 66 hours) back to the States for further refinement and distribution.
Beginning in 2013, scientists and engineers at GMIS set out to design a system for generating enough energy to make Mo99 without the need for a nuclear reactor and without the use of weapons-grade uranium. Designing, building and testing such a system required substantial private capital as well as a focused and dedicated group of nuclear physicists, radiochemists, mechanical and electrical engineers and professional managers. Numerous experiments were run using different target materials, energy levels and extraction techniques. Hundreds of advanced models were built testing every possible change in each of the many variables in the production processes to make Mo99.
The final result brought forth a system capable of making significant quantities of Mo99 without the need for a nuclear reactor and without the use of weapons-grade uranium. This system is compact, modular in design,environmentally friendly and uses many commercial-off-the-shelf (COTS) components readily available in the marketplace and uses an inert metal as its target material. The system can be placed in multiple locations across the U.S. and around the world allowing doctors and hospitals ready access to a consistent and reliable supply of Mo99 without the logistical challenges of transporting Mo99 from foreign countries.
The GMIS system will bring substantial amounts of U.S. based Mo99 to market for the first time in over 40 years. No longer will patients wait days and weeks for time-sensitive imaging procedures delayed or cancelled because of logistical problems in transporting Mo99 from thousands of miles away. GMIS’ multiple systems approach and its inherent redundancy ensures a consistent and reliable supply of Mo99 at all times. As a result, lives will be extended, lives will be saved and more patients will have ready access to the vital diagnostic and treatment tools that are enabled by medical radioisotopes.